Skip to main content
Caplight Logo









Elasmogen

Elasmogen

Private
AberdeenHealthcare & Life Scienceshttps://elasmogen.com/

Last Round

Series A

May 18, 2022

Total Funding Raised

$17.82M

Company Overview

Elasmogen is a biopharmaceutical company that develops therapeutic biologics, specifically soloMERs, for the treatment of cancer and inflammatory, autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

soloMERVNARvariable new antigen receptorsshark-derived therapeuticsbiologics R&Dprotein scaffoldsantibody-like therapeuticsdrug discoverybiotech partnershipspre-clinical developmentoncology therapeuticsimmunologyshark antibodiesnanobodiesbiotech licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Elasmogen Comparables

Compare Elasmogen with similar companies based on industry and business-model similarity.

Elasmogen comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ossianix
83%
Cortalix B.V.
82%
Singh Biotechnology
78%

Elasmogen Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 18, 2022
GrantJul 8, 2020
SeedJan 10, 2020
GrantMar 16, 2017
SeedMar 16, 2017
Seed
Feb 1, 2016

Key People

Founding team and executive leadership

Caroline Barelle

Chief Executive Officer and founder

Founding Team

Elasmogen Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 22, 2026

    Monthly visitors grew 72% MoM, from 576 to 993.

  • Apr 24, 2026

    Monthly visitors grew 36% MoM.

Elasmogen Filings

Explore SEC and related filing metadata, where available.

Elasmogen filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Elasmogen's valuation, stock price, and market status.

Is Elasmogen a public or private company?

Elasmogen is a private company.

What is the current stock price of Elasmogen?

Elasmogen is a private company with no public stock price. No recent secondary market data is available.

How much is Elasmogen worth (valuation)?

Valuation information for Elasmogen is not publicly available.

Can I buy Elasmogen stock?

Elasmogen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Elasmogen's last funding round?

Elasmogen's most recent funding round was Series A on May 18, 2022.

Who are the main investors in Elasmogen?

Key investors in Elasmogen include BGF, Deepbridge Capital, Scottish National Investment Bank.

Will Elasmogen IPO soon?

No public IPO plans have been announced for Elasmogen.

How can I track Elasmogen secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Elasmogen's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersAberdeen
Employee Range8
Year Founded2016
Last FundingMay 18, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?